Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503439 | 0.98 | ATM (0.48) | ATMALDH1A1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL14538084 | 0.98 | ATM (0.48) | ATMALDH1A1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL14538018 | 0.81 | ALDH1A1 (0.36) | ATMALDH1A1POLBL3MBTL1LMNA | |
| SCHEMBL14538081 | 0.80 | L3MBTL1 (0.70) | ALDH1A1SMN1; SMN2RAB9AHPGDPOLB | |
| SCHEMBL5181688 | 0.80 | TPSAB1 (0.51) | ALDH1A1POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL14538019 | 0.80 | ACHE (0.54) | ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3724641 | 0.79 | L3MBTL1 (0.68) | ALDH1A1SMN1; SMN2RAB9AHPGDPOLB | |
| SCHEMBL19703776 | 0.77 | ALDH1A1 (0.58) | ATMALDH1A1RAB9AHPGDMAPT | |
| SCHEMBL944668 | 0.76 | ALDH1A1 (0.53) | ATMALDH1A1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL28716383 | 0.76 | ALDH1A1 (0.50) | ATMALDH1A1SMN1; SMN2RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021038241-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2021-03-04 | — | — | WO | disclosed |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | ATM 1173/4885ALDH1A1 1688/4885SMN1; SMN2 3902/4885 |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | ATM 1173/4885ALDH1A1 1688/4885SMN1; SMN2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.